Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | BCL9 | O00512 | 8/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 8/20 | 0.34 |
| ▸ | GPR6 | P46095 | 3/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 3/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23122009 | 0.95 | HSD11B1 (0.37) | HSD11B1BCL9CTNNB1MGLLPRKAA2 | |
| SCHEMBL30008961 | 0.95 | HSD11B1 (0.37) | HSD11B1BCL9CTNNB1MGLLPRKAA2 | |
| Trifluoroacetic Acid SCHEMBL30009630 | 0.89 | PKM (0.40) | HSD11B1BCL9CTNNB1GPR6PKM | |
| SCHEMBL23121734 | 0.84 | HSD11B1 (0.38) | HSD11B1BCL9CTNNB1 | |
| SCHEMBL23123147 | 0.84 | HSD11B1 (0.37) | HSD11B1DDR1MGLLTSHR | |
| SCHEMBL23120508 | 0.83 | MGLL (0.39) | HSD11B1BCL9CTNNB1MGLLTSHR | |
| SCHEMBL29816896 | 0.83 | MGLL (0.39) | HSD11B1BCL9CTNNB1MGLLTSHR | |
| Hydrochloric Acid SCHEMBL23121732 | 0.83 | BCL9 (0.40) | HSD11B1BCL9CTNNB1MGLLTSHR | |
| Hydrochloric Acid SCHEMBL30009287 | 0.83 | BCL9 (0.40) | HSD11B1BCL9CTNNB1MGLLTSHR | |
| SCHEMBL23121109 | 0.82 | MGLL (0.40) | HSD11B1MGLLPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4041724-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | BRD9, BRD2, BRD1 | HSD11B1 972/4885BCL9 25/4885CTNNB1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.